OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 530 participants.

Also called NCT07137832

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 530 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07137832
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07137832. Randomized; single masking; primary purpose treatment. Start 2025-10-09 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion
Acronym
PEARL-MeVO
Condition
Acute Ischemic Stroke
Intervention (Combination product)
Primary intra-arterial thrombolysis
Intervention (Other)
Standard medical treatment
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct07137832
Content hash
b07a5bb98952d533ad11fe1597bbae9632a7bdc42c605a9036a88ac5aa1b8e28